Loading...
Market
Which region will have the highest early adoption of Lenacapavir by end of 2025?
2
Resolution / Starting Odds
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Health policy reports and pharmaceutical sales data
Story
Twice-Yearly HIV Prevention Shot: 96% Effective in Men, 100% in Women
Dec 1, 2024, 12:50 PM
A new study has shown that Lenacapavir, a twice-yearly injectable pre-exposure prophylaxis (PrEP), is highly effective in preventing HIV infections, with a 96% reduction in risk for men and 100% effectiveness in women. Despite its potential, concerns have been raised about equitable access, cost-effectiveness, and adherence challenges. Gilead, the developer of the drug, has announced plans to allow the sale of generic versions of Lenacapavir in 120 countries with high HIV rates to address affordability issues. The World Health Organization (WHO) is currently reviewing the drug for initial approval, which could significantly impact HIV prevention strategies globally.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
USA • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
United States • 25%
European Union • 25%
South Africa • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%